Conferences - Results from #380

ASCO 2024: Intensification of ADT with Enzalutamide in High-Risk Patients with Biochemical Relapse Following Radical Prostatectomy Undergoing Salvage Radiation: Initial Results from RTOG 3506 (STEEL) June 3, 2024

ASCO 2024: A Phase 1/2 Study of ONCT-534-101, a Dual-Action Androgen Receptor Inhibitor, in Patients with mCRPC June 3, 2024

ASCO 2024: Correlation of BMI with Survival Outcomes in Patients with mHSPC: Analysis of Patient-Level Data from SWOG 1216 Study June 3, 2024

ASCO 2024: IMPLEMENT: Physicians Use of First-Line Treatment Intensification in mCSPC: A Discrete Choice Experiment June 3, 2024

ASCO 2024: Cost Effectiveness Analysis of Nadofaragene Firadenovec for the Treatment of High-Risk, BCG–unresponsive, NMIBC from a US Third-Party Payer Perspective June 3, 2024

ASCO 2024: Real-World Baseline Treatment Patterns and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Olaparib in the United States June 3, 2024

ASCO 2024: SECuRE: A Dose Escalation/Expansion Study to Assess the Anti-Tumor Efficacy of 67Cu-SAR-bisPSMA in Patients with Metastatic Castrate Resistant Prostate Cancer June 3, 2024

ASCO 2024: Real-World Comparative Effectiveness and Cardiovascular Safety of Enzalutamide Versus Abiraterone Amongst Older Men Diagnosed with Metastatic Castration-Resistant Prostate Cancer June 3, 2024

ASCO 2024: Outcomes of Patients with BCG–unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Who Demonstrated Nonresponse to Pembrolizumab in KEYNOTE-057: A Post Hoc Analysis June 3, 2024

ASCO 2024: Final Results of a Phase I/II Dose-Escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive mCRPC June 3, 2024

ASCO 2024: Willingness of Patients with Biochemically Recurrent Prostate Cancer with Positive 18F-DCFPyL PET/CT PSMA to Monitor Without Treatment June 3, 2024

ASCO 2024: Exploration of Circulating Tumor Cell Conversion and CTC0 as Prognostic Biomarkers for Efficacy in TALAPRO-2 June 3, 2024

ASCO 2024: Prognostic Implications of PSA Levels at 7 Months in Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide: Landmark Analysis of ENZAMET (ANZUP 1304) June 3, 2024

ASCO 2024: EMBARK Post Hoc Analysis of Sexual Activity PROs in Patients Who Were Sexually Active or Interested in Sex at Baseline June 3, 2024

ASCO 2024: Treatment Outcomes for Patients with Ga68-PSMA-PET Prostate Cancer with or Without Conventional Imaging Correlates June 3, 2024

ASCO 2024: Phase 3 Study of Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001) June 3, 2024

ASCO 2024: Development of a Machine Learning Model to Predict the Outcome of Randomized Clinical Trials of Patients with Metastatic Prostate Cancer June 2, 2024

ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study June 2, 2024

ASCO 2024: Biomarkers Associated with Outcomes from KEYLYNK-010: Pembrolizumab plus Olaparib Versus Next-Generation Hormonal Agent in Previously Treated Metastatic Castration-Resistant Prostate Cancer June 2, 2024

ASCO 2024: Matching-Adjusted Indirect Comparisons of Talazoparib plus Enzalutamide Versus Olaparib plus Abiraterone and Prednisolone for First-Line Therapy in Patients with mCRPC and HRR Mutations/BRCAm June 2, 2024

Page 20 of 589